Recent developments in Adenosine A2A receptor ligands

Handbook of Experimental Pharmacology

Volumn 193, Issue , 2009, Pages 59-98

  Cristalli, Gloria ^a   Müller, Christa E ^b   Volpini, Rosaria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

A2A agonists; A2A antagonists; Adenines; Adenosine A2A receptor; Adenosine receptor; Nitrogen (poly)heterocyclic compounds; Nucleosides; Xanthines

Indexed keywords

1,3 DIPROPYL 7 METHYL 8 [2 (3 THIENYL)ETHENYL]XANTHINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 ANILINOADENOSINE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 HEXYNYLADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 O METHYL 1 PROPARGYLXANTHINE; 2 PHENYLETHYNYLADENOSINE; 2 PHENYLHYDROXYPROPYNYLADENOSINE; 3 (3 HYDROXYPROPYL) 8 (3 METHOXYSTYRYL) 1 PROPARGYLXANTHINE; 3,7 DIMETHYL 1 PROPARGYL 8 (3 BROMOSTYRYL)XANTHINE; 3,7 DIMETHYL 1 PROPARGYL 8 (3 CHLOROSTYRYL)XANTHINE; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 4 AMINO 8 CHLORO 1 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N CYCLOPENTYLADENOSINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANR 152; ANR 94; ASP 5854; BIIB 014; BINODENOSON; CVT 2008; CVT 3033; CYCLOHEXYLADENOSINE; ISTRADEFYLLINE; LEXISCAN; LU AA47040; N 6 (2 PHENYLISOPROPYL)ADENOSINE; PRELADENANT; REGADENOSON; SCH 420814; SHA 174; ST 1535; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 6497; VER 6623; VER 7835; LIGAND;

DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEART MUSCLE PERFUSION; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION;

ANIMALS; HUMANS; LIGANDS; RECEPTOR, ADENOSINE A2A;

EID: 70349303799     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-89615-9_3     Document Type: Review

References (221)

1. Abiru T, Miyashita T, Watanabe Y, Yamaguchi T, Machida H, Matsuda A (1992) Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects. J Med Chem 35:2253-2260
2. Abiru T, Endo K, Machida H (1995) Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Eur J Pharmacol 281:9-15
3. Akkari R, Burbiel JC, Hockemeyer J, Müller CE (2006) Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem 6:1375-1399
4. Alanine A, Anselm L, Steward L, Thomi S, Vifian W, Groaning MD (2004) Synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor antagonists. Bioorg Med Chem Lett 14:817-821
5. Alexander SP, Millns PJ (2001) [3H]ZM241385-an antagonist radioligand for adenosine A2A receptors in rat brain. Eur J Pharmacol 411:205-210
6. Baraldi PG, Manfredini S, Simoni D, Zappaterra L, Zocchi C, Dionisotti S, Ongini E (1994) Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4, 5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2A adenosine receptor antagonists. Bioorg Med Chem Lett 4:2539-2544
7. Baraldi PG, Cacciari B, Spalluto G, Pineda de las Infantas y Villatoro MJ, Zocchi C, Dionisotti S, Ongini E (1996a) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine derivatives: potent and selective A2A adenosine antagonists. J Med Chem 39:1164-1171
8. Baraldi PG, Cacciari B, Spalluto G, Pineda de las Infants MJ, Zocchi C, Ferrara S, Dionisotti S, Ferra DS (1996b) 1,2,3-Triazolo[5,4-e]1,2,4-triazolo[1, 5-c]pyrimidine derivatives: a new class of A2A adenosine receptor antagonists. Farmaco 51:297-300 (Pubitemid 26244849)
9. Baraldi PG, Cacciari B, Pineda de Las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park KS, Ji XD, Jacobson KA (1998a) Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5--N-ethyluronamide as A1 and A3 adenosine receptor agonists. J Med Chem 41:3174-3185
10. Baraldi PG, Cacciari B, Spalluto G, Bergonzoni M, Dionisotti S, Ongini E, Varani K, Borea PA (1998b) Design, synthesis, and biological evaluation of a second generation of pyrazolo[4, 3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. J Med Chem 41:2126-2133
11. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Moro S, Klotz KN, Leung E, Varani K, Gessi S, Merighi S, Borea PA (2000) Pyrazolo[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. J Med Chem 43:4768-4780
12. Baraldi PG, Cacciari B, Romagnoli R, Klotz KN, Spalluto G, Varani K, Gessi S, Merighi S, Borea PA (2001) Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine derivatives as adenosine receptor ligands: a starting point for searching for A2B adenosine receptor antagonists. Drug Dev Res 53:225-235
13. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, Varani K, Borea PA (2002) 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2, 4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 45:115-126
14. Baraldi PG, Tabrizi MA, Gessi S, Borea PA (2008) Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 108:238-263
15. Beukers MW, Chang LC, von Frijtag Drabbe Kunzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, IJzerman AP (2004) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707-3709
16. Bilkei-Gorzo A, Abo-Salem OM, Hayallah AM, Michel K, Müller CE, Zimmer A (2008) Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol 377:65-76
17. Bosch MP, Campos F, Niubo I, Rosell G, Diaz JL, Brea J, Loza MI, Guerrero A (2004) Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. J Med Chem 47:4041-4053
18. Brambilla R, Cottini L, Fumagalli M, Ceruti S, Abbracchio MP (2003) Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43:190-194
19. Bruns RF (1980) Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol 58:673-691
20. Bruns RF, Lu GH, Pugsley TA (1986) Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 29:331-346
21. Cacciari B, Pastorin G, Spalluto G (2003) Medicinal chemistry of A2A adenosine receptor antagonists. Curr Top Med Chem 3:403-411
22. Camaioni E, Di Francesco E, Vittori S, Volpini R, Cristalli G (1997) Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl- 1-propyn-1-yl)NECA. Bioorg Med Chem 5:2267-2275
23. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G (1998) New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 6:523-533
24. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, Casado V, Canela EI, Lluis C, Goldberg SR, Moratalla R, Franco R, Ferŕe S (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32:2249-2259
25. Caulkett PWR, Jones G, McPartlin M, Renshaw ND, Stewart SK, Wright B (1995) Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions. J Chem Soc Perkin Trans 1:801
26. Chebib M, McKeveney D, Quinn RJ (2000) 1-Phenylpyrazolo[3,4-d] pyrimidines; structure- activity relationships for C6 substituents at A1 and A2A adenosine receptors. BioorgMed Chem 8:2581-2590
27. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (1999) 4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1, 2,4-triazolo [4,3-alpha]-quinoxalin 1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors. Arch Pharm 332:39-41
28. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (2000) 1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J Med Chem 43:1158-1164
29. Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (2003) Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4- triazolo[4,3-a]quinoxalin-1-one derivatives as potent A2A adenosine receptor antagonists. Bioorg Med Chem 11:5509-5518
30. Cristalli G (2000) Patent no WO2001062768
31. Cristalli G, GrifantiniM, Vittori S, BalduiniW, Cattabeni F (1985) Adenosine and 2-chloadenosine deaza analogues as adenosine receptor agonists. Nucleosides Nucleotides 4:625-639
32. Cristalli G, Franchetti P, Grifantini M, Vittori S, Klotz KN, Lohse MJ (1988) Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem 31:1179-1183
33. Cristalli G, Eleuteri A, Vittori S, Volpini R, Lohse MJ, Klotz KN (1992) 2-Alkynyl derivatives of adenosine and adenosine-5--N-ethyluronamide as selective agonists at A2 adenosine receptors. J Med Chem 35:2363-2368
34. Cristalli G, Vittori S, Thompson RD, Padgett WL, Shi D, Daly JW, Olsson RA (1994a) Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol 349:644-650
35. Cristalli G, Volpini R, Vittori S, Camaioni E, Monopoli A, Conti A, Dionisotti S, Zocchi C, Ongini E (1994b) 2-Alkynyl derivatives of adenosine-5--N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation. JMed Chem 37:1720-1726
36. Cristalli G, Camaioni E, Vittori S, Volpini R, Borea PA, Conti A, Dionisotti S, Ongini E, Monopoli A (1995) 2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5--Nethyluronamide as selective A2A adenosine receptor agonists. J Med Chem 38:1462-1472
37. Cristalli G, Camaioni E, Di Francesco E, Volpini R, Vittori S (1996) Chemical and pharmacological profile of selective adenosine receptor agonists. In: Giardiǹa D, Piergentili S, Pigini M (eds) Perspectives in receptor research. Pharmaco Chemistry Library, Elsevier, Amsterdam, pp 165-180
38. Cristalli G, Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN (1998) Characterization of potent ligands at human recombinant adenosine receptors. Drug Dev Res 45:176-181
39. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E (2001) Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev 21:105-128
40. Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003) Medicinal chemistry of adenosine A2A receptor agonists. Curr Top Med Chem 3:387-401
41. Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R (2007) Highlights on the development of A2A adenosine receptor agonists and antagonists. ChemMedChem 2:260-281
42. Cusack NJ, Hourani SM (1981) 5--N-Ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol 72:443-447
43. CVT (2008) CV Therapeutics and Astellas announce FDA approval for Lexiscan(TM) (regadenoson) injection. http://www.cvt.com/PressRelease.aspx? releaseID=1128317
44. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A2A receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203:241-245
45. Daly JW (1982) Adenosine receptors: targets for future drugs. J Med Chem 25:197-207
46. Daly JW, Padgett WL, ShamimMT (1986) Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem 29:1305-1308
47. Daly JW, Hide I, Müller CE, Shamim M (1991) Caffeine analogs: structure-activity relationships at adenosine receptors. Pharmacology 42:309-321
48. Daly JW, Padgett WL, Secunda SI, Thompson RD, Olsson RA (1993) Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology 46:91-100
49. de Zwart M, Link R, von Frijtag Drabbe Kunzel JK, Cristalli G, Jacobson KA, Townsend- Nicholson A, IJzerman AP (1998) A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. Nucleosides Nucleotides 17:969-985
50. de Zwart M, Kourounakis A, Kooijman H, Spek AL, Link R, von Frijtag Drabbe Kunzel JK, IJzerman AP (1999a) 5--N-substituted carboxamidoadenosines as agonists for adenosine receptors. J Med Chem 42:1384-1392
51. de Zwart M, Vollinga RC, Beukers MW, Sleegers DF, Von Frijtag Drabbe Künzel J, de Groote M, IJzerman AP (1999b) Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Dev Res 48:95-103
52. Del Giudice MR, Borioni A, Mustazza C, Gatta F, Dionisotti S, Zocchi C, Ongini E (1996) (E)- 1-(Heterocyclyl or cyclohexyl)-2-[1,3,7- trisubstituted(xanthin-8-yl)]ethenes as adenosine A2A receptors antagonists. Eur J Med Chem 31:59-63
53. DeMet EM, Chicz-DeMet A (2002) Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385. Naunyn-Schmiedeberg's Arch Pharmacol 366:478-481
54. Dionisotti S, Conti A, Sandoli D, Zocchi C, Gatta F, Ongini E (1994) Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8-substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br J Pharmacol 112:659-665
55. Dionisotti S, Ferrara S, Molta C, Zocchi C, Ongini E (1996) Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261. J Pharmacol Exp Ther 278:1209-1214
56. Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm BB (1997) Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol 121:353-360 (Pubitemid 27226284)
57. Dowling JE, Vessels JT, Haque S, Chang HX, van Vloten K, Kumaravel G, Engber T, Jin X, Phadke D, Wang J, Ayyub E, Petter RC (2005) Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists. Bioorg Med Chem Lett 15:4809-4813
58. Drabczynska A, Schumacher B, Müller CE, Karolak-Wojciechowska J, Michalak B, Pekala E, Kiec-Kononowicz K (2003) Impact of the aryl substituent kind and distance from pyrimido[2, 1-f ]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur J Med Chem 38:397-402
59. Drabczynska A, Müller CE, Schumacher B, Hinz S, Karolak- Wojciechowska J, Michalak B, Pekala E, Kiec-Kononowicz K (2004) Tricyclic oxazolo[2,3-f]purinediones: potency as adenosine receptor ligands and anticonvulsants. Bioorg Med Chem 12:4895-4908
60. Drabczynska A, Müller CE, Lacher SK, Schumacher B, Karolak-Wojciechowska J, Nasal A, Kawczak P, Yuzlenko O, Pekala E, Kiec-Kononowicz K (2006) Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones. Bioorg Med Chem 14:7258-7281
61. Drabczynska A, Müller CE, Schiedel A, Schumacher B, Karolak-Wojciechowska J, Fruzinski A, Zobnina W, Yuzlenko O, Kiec-Kononowicz K (2007) Phenylethyl-substituted pyrimido[2, 1-f ]purinediones and related compounds: structure-activity relationships as adenosine A1 and A2A receptor ligands. Bioorg Med Chem 15:6956-6974
62. Eggbrecht H, Gossl M (2006) Regadenoson (CV Therapeutics/Astellas). Curr Opin Investig Drugs 7:264-271
63. El Yacoubi M, Ledent C, Parmentier M, Ongini E, Costentin J, Vaugeois JM (2001) In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur J Neurosci 14:1567-1570
64. Erickson RH, Hiner RN, Feeney SW, Blake PR, Rzeszotarski WJ, Hicks RP, Costello DG, Abreu ME (1991) 1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity. J Med Chem 34:1431-1435
65. Ferŕe S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I (2007) Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog Neurobiol 83:332-347
66. Ferŕe S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K, Quiroz C, Justinova Z, Lluis C, Franco R, Goldberg SR (2008) Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13:2391-2399
67. Flhor A, Riemer C (2006) Patent no. WO 200507592
68. Francis JE, Cash WD, Psychoyos S, Ghai G, Wenk P, Friedmann RC, Atkins C, Warren V, Furness P, Hyun JL, Stone GA, Desai M, Williams M (1988) Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J Med Chem 31:1014-1020
69. Francis JE, Webb RL, Ghai GR, Hutchison AJ, Moskal MA, deJesus R, Yokoyama R, Rovinski SL, Contardo N, Dotson R, Barclay B, Stone GA, Jarvis MF (1991) Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines. J Med Chem 34:2570-2579
70. Fredholm BB, Lindstrom K, Dionisotti S, Ongini E (1998) [3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 70:1210-1216 (Pubitemid 28113656)
71. Fredholm BB, B̈attig K, Holḿen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133
72. Fuxe K, Marcellino D, Genedani S, Agnati L (2007) Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease. Mov Disord 22:1990-2017
73. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, Palle V, Zablocki JA, Blackburn B, Belardinelli L (2001) Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 298:209-218
74. Gao ZG, Mamedova LK, Chen P, Jacobson KA (2004) 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol 68:1985-1993
75. Gatta F, Del Giudice MR, Borioni A, Borea PA, Dionisotti S, Ongini E (1993) Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i] purines: new potent adenosine A2 receptor antagonists. Eur J Med Chem 28:569-577
76. Gessi S, Varani K, Merighi S, Ongini E, Borea PA (2000) A2A adenosine receptors in human peripheral blood cells. Br J Pharmacol 129:2-11
77. Gonzalez MP, Teran C, Teijeira M, Gonzalez-Moa MJ (2005) GETAWAY descriptors to predicting A2A adenosine receptors agonists. Eur J Med Chem 40:1080-1086 (Pubitemid 41446277)
78. Gordi T (2006) Patent no. WO2006044856
79. Grahner B, Winiwarter S, Lanzner W, Müller CE (1994) Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. J Med Chem 37:1526-1534
80. Hasan A, Hussain T, Mustafa SJ, Srivastava PC (1994) 2-Substituted thioadenine nucleoside and nucleotide analogues: synthesis and receptor subtype binding affinities (1). Bioconjug Chem 5:364-369
81. Hirani E, Gillies J, Karasawa A, Shimada J, Kase H, Opacka-Juffry J, Osman S, Luthra SK, Hume SP, Brooks DJ (2001) Evaluation of [4-O-methyl-11C]KW- 6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats. Synapse 42:164-176
82. Hockemeyer J, Burbiel JC, Müller CE (2004) Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 69:3308-3318
83. Holschbach MH, Bier D, Stusgen S, Wutz W, Sihver W, Coenen HH, Olsson RA (2006) Synthesis and evaluation of 7-amino-2-(2(3)-furyl)-5-phenylethylamino- oxazolo[5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem 41:7-15
84. Homma H, Watanabe Y, Abiru T, Murayama T, Nomura Y, Matsuda A (1992) Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5--uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity. J Med Chem 35:2881-2890
85. Hutchison AJ, Webb RL, Oei HH, Ghai GR, Zimmerman MB, Williams M (1989) CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther 251:47-55
86. Hutchison AJ, Williams M, de Jesus R, Yokoyama R, Oei HH, Ghai GR, Webb RL, Zoganas HC, Stone GA, Jarvis MF (1990) 2-(Arylalkylamino)adenosin-5-- uronamides: a new class of highly selective adenosine A2 receptor ligands. J Med Chem 33:1919-1924
87. IJzerman AP, Von Frijtag Drabbe Kuenzel JK, Vittori S, Cristalli G (1994) Purine-substituted adenosine derivatives with small N6-substituents as adenosine receptor agonists. Nucleosides Nucleotides 13:2267-2281
88. IJzerman AP, van der Wenden NM (1997) Modulators of adenosine uptake, release, and inactivation. In: Jacobson KA, Jarvis MF (eds) Purinergic approaches in experimental therapeutics. Wiley-Liss, New York, pp 129-148
89. Impagnatiello F, Bastia E, Ongini E, Monopoli A (2000) Adenosine receptors in neurological disorders. Emerg Ther Targets 4:635-663
90. Ishiwata K, Noguchi J, Toyama H, Sakiyama Y, Koike N, Ishii S, Oda K, Endo K, Suzuki F, Senda M (1996) Synthesis and preliminary evaluation of [11C]KF17837, a selective adenosine A2A antagonist. Appl Radiat Isot 47:507-511
91. Ishiwata K, Sakiyama Y, Sakiyama T, Shimada J, Toyama H, Oda K, Suzuki F, Senda M (1997) Myocardial adenosine A2A receptor imaging of rabbit by PET with [11C]KF17837. Ann Nucl Med 11:219-225
92. Ishiwata K, Noguchi J, Wakabayashi S, Shimada J, Ogi N, Nariai T, Tanaka A, Endo K, Suzuki F, Senda M (2000a) 11C-labeled KF18446: a potential central nervous system adenosine A2A receptor ligand. J Nucl Med 41:345-354
93. Ishiwata K, Ogi N, Shimada J, Nonaka H, Tanaka A, Suzuki F, SendaM(2000b) Further characterization of a CNS adenosine A2A receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann Nucl Med 14:81-89
94. Ishiwata K, Shimada J, Wang WF, Harakawa H, Ishii S, Kiyosawa M, Suzuki F, Senda M (2000c) Evaluation of iodinated and brominated [11C]styrylxanthine derivatives as in vivo radioligands mapping adenosine A2A receptor in the central nervous system. Ann Nucl Med 14:247-253
95. Ishiwata K, Ogi N, Hayakawa N, Oda K, Nagaoka T, Toyama H, Suzuki F, Endo K, Tanaka A, Senda M (2002) Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging. Ann Nucl Med 16:467-475
96. Ishiwata K, Kawamura K, Kimura Y, Oda K, Ishii K (2003a) Potential of an adenosine A2A receptor antagonist [11C]TMSX for myocardial imaging by positron emission tomography: a first human study. Ann Nucl Med 17:457-462
97. Ishiwata K,Wang WF, Kimura Y, Kawamura K, Ishii K (2003b) Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann Nucl Med 17:205-211
98. Jackson EK, HerzerWA, Suzuki F (1993) KF17837 is an A2 adenosine receptor antagonist in vivo. J Pharmacol Exp Ther 267:1304-1310
99. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264
100. Jacobson KA, Kirk KL, PadgettW, Daly JW (1985) Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett 184:30-35
101. Jacobson KA, Ukena D, Kirk KL, Daly JW (1986) [3H]Xanthine amine congener of 1,3-dipropyl- 8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci USA 83:4089-4093
102. Jacobson KA, Gallo-Rodriguez C,Melman N, Fischer B, MaillardM, van Bergen A, van Galen PJ, Karton Y (1993a) Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem 36:1333-1342
103. Jacobson KA, Shi D, Gallo-Rodriguez C, Manning M, Jr., Müller C, Daly JW, Neumeyer JL, Kiriasis L, Pfleiderer W (1993b) Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. J Med Chem 36:2639-2644
104. Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, Meshulam Y, Stiles GL, Kim HO (1995) Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem 38:1720-1735
105. Jacobson KA, Ji X, Li AH, Melman N, Siddiqui MA, Shin KJ, Marquez VE, Ravi RG (2000) Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem 43:2196-2203
106. Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M (1989) [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther 251:888-893
107. Ji XD, Jacobson KA (1999) Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov 16:217-226
108. Kalda A, Yu L, Oztas E, Chen JF (2006) Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 248:9-15
109. Kelly M, Bailey A, Ledent C, Kitchen I, Hourani S (2004) Characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A receptor knockout mice. Eur J Pharmacol 504:55-59
110. Kiec-Kononowicz K, Drabczynska A, Pekala E, Michalak B, Müller CE, Schumacher B, Karolak- Wojciechowska J, Duddeck H, Rockitt S,Wartchow R (2001) New developments in A1 and A2 adenosine receptor antagonists. Pure Appl Chem 73:1411-1420
111. Kim YC, Ji XD, Jacobson KA (1996) Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem 39:4142-4148
112. Kiselgof E, Tulshian DB, Arik L, Zhang H, Fawzi A (2005) 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett 15:2119-2122 (Pubitemid 40445479)
113. Klotz KN (2000) Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Arch Pharmacol 362:382-391
114. Klotz KN, Lohse MJ, Schwabe U, Cristalli G, Vittori S, Grifantini M (1989) 2-Chloro-N6- [3H]cyclopentyladenosine ([3H]CCPA)-a high affinity agonist radioligand for A1 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 340:679-683
115. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes- characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 357:1-9
116. Klotz KN, Camaioni E, Volpini R, Kachler S, Vittori S, Cristalli G (1999) 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 360:103-108
117. Klotz KN, Kachler S, Lambertucci C, Vittori S, Volpini R, Cristalli G (2003) 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn-Schmiedeberg's Arch Pharmacol 367:629-634
118. Knutsen LJ, Weiss SM (2001) KW-6002 (Kyowa Hakko Kogyo). Curr Opin Investig Drugs 2:668-673
119. Knutsen LJ, Lau J, Petersen H, Thomsen C,Weis JU, Shalmi M, Judge ME, Hansen AJ, Sheardown MJ (1999) N-substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects. J Med Chem 42:3463-3477
120. Lambertucci C, Volpini R, Costanzi S, Taffi S, Vittori S, Cristalli G (2003) 2- Phenylhydroxypropynyladenosine derivatives as high potent agonists at A2B adenosine receptor subtype. Nucleosides Nucleotides Nucleic Acids 22:809-812
121. Lambertucci C, Cristalli G, Dal Ben D, Kachare DD, Bolcato C, Klotz KN, Spalluto G, Volpini R (2007a) New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal 3:339-346
122. Lambertucci C, Vittori S, Mishra RC, Dal Ben D, Klotz KN, Volpini R, Cristalli G (2007b) Synthesis and biological activity of trisubstituted adenines as A2A adenosine receptor antagonists. Nucleosides Nucleotides Nucleic Acids 26:1443-1446
123. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 388:674-678
124. Lohse MJ, Klotz KN, Schwabe U, Cristalli G, Vittori S, Grifantini M (1988) 2-Chloro-N6- cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn- Schmiedeberg's Arch Pharmacol 337:687-689
125. Marian T, Boros I, Lengyel Z, Balkay L, Horvath G, Emri M, Sarkadi E, Szentmiklosi AJ, Fekete I, Tron L (1999) Preparation and primary evaluation of [11C]CSC as a possible tracer for mapping adenosine A2A receptors by PET. Appl Radiat Isot 50:887-893
126. Massip S, Guillon J, Bertarelli D, Bosc JJ, Leger JM, Lacher S, Bontemps C, Dupont T, Müller CE, Jarry C (2006) Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy- 3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists. Bioorg Med Chem 14:2697-2719
127. Matasi JJ, Caldwell JP, Hao J, Neustadt B, Arik L, Foster CJ, Lachowicz J, Tulshian DB (2005) The discovery and synthesis of novel adenosine receptor (A2A) antagonists. Bioorg Med Chem Lett 15:1333-1336
128. Mathot RA, Van der Wenden EM, Soudijn W, IJzerman AP, Danhof M (1995) Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br J Pharmacol 116:1957-1964
129. Matova MM, Nacheva RN, Boicheva SV (1997) QSAR analysis of 2-alkyloxy and 2-aralkyloxy adenosine A1- and A2-agonists. Eur J Med Chem 32:505-513
130. Matsuda A, Shinozaki M, Yamaguchi T, Homma H, Nomoto R, Miyasaka T,Watanabe Y, Abiru T (1992) Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects. J Med Chem 35:241-252
131. Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F (2006) The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 1073-1074:470-480
132. Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N (2007) Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]- 1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther 323:708-719
133. Minetti P, Tinti MO, Carminati P, Castorina M, Di Cesare MA, Di Serio S, Gallo G, Ghirardi O, Giorgi F, Giorgi L, Piersanti G, Bartoccini F, Tarzia G (2005) 2-n-Butyl-9-methyl-8- [1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 48:6887-6896
134. Mishina M, Ishiwata K, Kimura Y, NaganawaM, Oda K, Kobayashi S, Katayama Y, Ishii K (2007) Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse 61:778-784
135. Monopoli A, Conti A, Zocchi C, Casati C, Volpini R, Cristalli G, Ongini E (1994) Pharmacology of the new selective A2A adenosine receptor agonist 2-hexynyl-5--N-ethylcarboxamidoadenosine. Arzneimittelforschung 44:1296-1304
136. Monopoli A, Lozza G, Forlani A,Mattavelli A, Ongini E (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9:3955-3959
137. Moro S, Gao ZG, Jacobson KA, Spalluto G (2006) Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 26:131-159
138. Müller CE (2000a) Adenosine receptor ligands-recent developments, part I. Agonists. Curr Med Chem 7:1269-1288
139. Müller CE (2000b) A2A Adenosine receptor antagonists-future drugs for Parkinson's disease? Drugs Fut 25:1043
140. Müller CE, Ferŕe S (2007) Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Patents CNS Drug Discov 2:1-21
141. Müller CE, Scior T (1993) Adenosine receptors and their modulators. Pharm Acta Helv 68:77-111
142. Müller CE, Stein B (1996) Adenosine receptor antagonists: structures and potential therapeutic applications. Curr Pharm Des 2:501-530
143. Müller CE, Geis U, Hipp J, Schobert U, FrobeniusW, PawlowskiM, Suzuki F, Sandoval-Ramirez J (1997a) Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. J Med Chem 40:4396-4405
144. Müller CE, Sauer R, Geis U, Frobenius W, Talik P, Pawlowski M (1997b) Aza-analogs of 8-styrylxanthines as A2A-adenosine receptor antagonists. Arch Pharm 330:181-189
145. Müller CE, Schobert U, Hipp J, Geis U, Frobenius W, Pawlowski M (1997c) Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonist. Eur J Med Chem 32:709-719
146. Müller CE, Deters D, Dominik A, Pawlowski M (1998a) Syntheses of paraxanthine and isoparaxanthine analogs (1,7- and 1,9-substituted xanthine derivatives). Synthesis 93:1428-1436
147. Müller CE, Sandoval-Ramirez J, Schobert U, Geis U, Frobenius W, Klotz KN (1998b) 8- (Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. Bioorg Med Chem 6:707-719
148. Müller CE, Maurinsh J, Sauer R (2000) Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8- (m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes-a new, selective antagonist radioligand for A2A adenosine receptors. Eur J Pharm Sci 10:259-265
149. Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, Daly JW (2002) Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A2Aand A3-adenosine receptor antagonists. J Med Chem 45:3440-3450
150. Murphree LJ, Marshall MA, Rieger JM, MacDonald TL, Linden J (2002) Human A2A adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4). Mol Pharmacol 61:455-462
151. Neustadt BR, Hao J, Lindo N, Greenlee WJ, Stamford AW, Tulshian D, Ongini E, Hunter J, Monopoli A, Bertorelli R, Foster C, Arik L, Lachowicz J, Ng K, Feng KI (2007) Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines. Bioorg Med Chem Lett 17:1376-1380
152. Niiya K, Olsson RA, Thompson RD, Silvia SK, Ueeda M (1992a) 2-(N-- alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. J Med Chem 35:4557-4561 (Pubitemid 23006672)
153. Niiya K, Thompson RD, Silvia SK, Olsson RA (1992b) 2-(N-- aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators. J Med Chem 35:4562-4566 (Pubitemid 23006673)
154. Nonaka Y, Shimada J, Nonaka H, Koike N, Aoki N, Kobayashi H, Kase H, Yamaguchi K, Suzuki F (1993) Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-dipropyl- 8-(3,4-dimethoxystyryl)-7- methylxanthine. J Med Chem 36:3731-3733
155. Nonaka H, Ichimura M, Takeda M, Nonaka Y, Shimada J, Suzuki F, Yamaguchi K, Kase H (1994a) KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7- methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur J Pharmacol 267:335-341
156. Nonaka H, Mori A, Ichimura M, Shindou T, Yanagawa K, Shimada J, Kase H (1994b) Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes. Mol Pharmacol 46:817-822
157. Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA (2004) Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg Med Chem 12:2995-3007
158. Palmer TM, Poucher SM, Jacobson KA, Stiles GL (1995) 125I-4-(2-[7-Amino- 2-[2-furyl] [1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2A adenosine receptor. Mol Pharmacol 48:970-974
159. Pedata F, Gianfriddo M, Turchi D, Melani A (2005) The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol Res 27:169-174
160. Peng H, Kumaravel G, Yao G, Sha L, Wang J, Van Vlijmen H, Bohnert T, Huang C, Vu CB, Ensinger CL, Chang H, Engber TM, Whalley ET, Petter RC (2004) Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J Med Chem 47:6218-6229 (Pubitemid 39587246)
161. Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N (2003) Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg Med Chem 11:1299-1310
162. Pfleger K, Seifen E, Schondorf H (1969) Inosine potentiation of the effect of adenosine on the heart. Biochem Pharmacol 18:43-51
163. Pinna A, Wardas J, Cristalli G, Morelli M (1997) Adenosine A2A receptor agonists increase Foslike immunoreactivity in mesolimbic areas. Brain Res 759:41-49
164. Pinna A, Volpini R, Cristalli G, MorelliM(2005) New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur J Pharmacol 512:157-164
165. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, Coll MG (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2A selective adenosine receptor antagonist. Br J Pharmacol 115:1096-1102
166. Prasad RN, Bariana DS, Fung A, SavicM, Tietje K, Stein HH, Brondyk H, Egan RS (1980) Modification of the 5- position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5--(N-substituted) carboxamides. J Med Chem 23:313-319
167. Richardson PJ, Kase H, Jenner PG (1997) Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 18:338-344
168. Rieger JM, Brown ML, Sullivan GW, Linden J, Macdonald TL (2001) Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. J Med Chem 44:531-539
169. Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B, Clark K, Font L, Korbey S, Sager TN, Hockemeyer J, Müller CE (2008) Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 13:3594-3605
170. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK (1990) 4-Amino [1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 33:2240-2254
171. Sauer R, Maurinsh J, Reith U, Fülle F, Klotz KN, Müller CE (2000) Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A2A-selective adenosine receptor antagonists. J Med Chem 43:440-448
172. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novere N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G (2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5:845-854
173. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
174. Seale TW, Abla KA, Shamim MT, Carney JM, Daly JW (1988) 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci 43:1671-1684
175. Shamim MT, Ukena D, Padgett WL, Daly JW (1989) Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J Med Chem 32:1231-1237
176. Shimada J, Koike N, Nonaka H, Shiozaki S, Yanagawa K, Kanda T, Kobayashi H, Ichimura M, Nakamura J, Kase H, Suzuki F (1997) Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett 7:2349-2352
177. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist JA 3rd, Schneller SW, Cristalli G, et al. (1995) Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem 38:1174-1188
178. Silverman LS, Caldwell JP, Greenlee WJ, Kiselgof E, Matasi JJ, Tulshian DB, Arik L, Foster C, Bertorelli R, Monopoli A, Ongini E (2007) 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists. Bioorg Med Chem Lett 17:1659-1662
179. Slee DH, Chen Y, Zhang X, Moorjani M, Lanier MC, Lin E, Rueter JK, Williams JP, Lechner SM, Markison S, Malany S, Santos M, Gross RS, Jalali K, Sai Y, Zuo Z, Yang C, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Diaz JL, Saunders J (2008a) 2-Amino-N-pyrimidin-4- ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents. J Med Chem 51:1719-1729
180. Slee DH, Moorjani M, Zhang X, Lin E, Lanier MC, Chen Y, Rueter JK, Lechner SM, Markison S, Malany S, Joswig T, Santos M, Gross RS, Williams JP, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Diaz JL, Jalali K, Sai Y, Zuo Z, Yang C, Wen J, O'Brien Z, Petroski R, Saunders J (2008b) 2-Amino-N-pyrimidin-4- ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships. J Med Chem 51:1730-1739
181. Slee DH, Zhang X, Moorjani M, Lin E, Lanier MC, Chen Y, Rueter JK, Lechner SM, Markison S, Malany S, Joswig T, Santos M, Gross RS,Williams JP, Castro-Palomino JC, CrespoMI, Prat M, Gual S, Diaz JL, Wen J, O'Brien Z, Saunders J (2008c) Identification of novel, water-soluble, 2-amino-N-pyrimidin- 4-yl acetamides as A2A receptor antagonists with in vivo efficacy. JMed Chem 51:400-406
182. Svenningsson P, Nomikos GG, Ongini E, Fredholm BB (1997) Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79:753-764
183. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13:2614-2632
184. Taylor MD, Moos WH, Hamilton HW, Szotek DS, Patt WC, Badger EW, Bristol JA, Bruns RF, Heffner TG, Mertz TE (1986) Ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem 29:346-353
185. Thorsell A, Johnson J, Heilig M (2007) Effect of the adenosine A2A receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar rats. Alcohol Clin Exp Res 31:1302-1307
186. Todde S, Moresco RM, Simonelli P, Baraldi PG, Cacciari B, Spalluto G, Varani K, Monopoli A, Matarrese M, Carpinelli A, Magni F, Kienle MG, Fazio F (2000) Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography. J Med Chem 43:4359-4362
187. Ukena D, Jacobson KA, Kirk KL, Daly JW (1986) A [3H]amine congener of 1,3-dipropyl-8- phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. FEBS Lett 199:269-274
188. Uustare A, Vonk A, Terasmaa A, Fuxe K, Rinken A (2005) Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. Life Sci 76:1513-1526
189. van den Berg D, Zoellner KR, Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP (2007) Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg Med Chem 15:3692-3702
190. van der Wenden EM, von Frijtag Drabbe Kunzel JK, Mathot RA, Danhof M, IJzerman AP, Soudijn W (1995) Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J Med Chem 38:4000-4006
191. van der Wenden EM, Carnielli M, Roelen HC, Lorenzen A, von Frijtag Drabbe Kunzel JK, IJzerman AP (1998) 5--Substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. J Med Chem 41:102-108
192. van Tilburg EW, GremmenM, von Frijtag Drabbe Kunzel J, de GrooteM, IJzerman AP (2003) 2,8- Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. Bioorg Med Chem 11:2183-2192
193. Vittori S, Camaioni E, Di Francesco E, Volpini R, Monopoli A, Dionisotti S, Ongini E, Cristalli G (1996) 2-Alkenyl and 2-alkyl derivatives of adenosine and adenosine-5--N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors. J Med Chem 39:4211-4217
194. Vittori S, Lorenzen A, Stannek C, Costanzi S, Volpini R, IJzerman AP, Kunzel JK, Cristalli G (2000) N-Cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor. J Med Chem 43:250-260
195. Vittori S, Costanzi S, Lambertucci C, Portino FR, Taffi S, Volpini R, Klotz KN, Cristalli G (2004) A2B adenosine receptor agonists: synthesis and biological evaluation of 2- phenylhydroxypropynyl adenosine and NECA derivatives. Nucleosides Nucleotides Nucl Acids 23:471-481
196. Vittori S, Volpini R, Lambertucci C, Taffi S, Klotz KN, Cristalli G (2005) 2-Substituted 5′-N-methylcarboxamidoadenosine (MECA) derivatives as A3 adenosine receptor ligands. Nucleosides Nucleotides Nucl Acids 24:935-938
197. Viziano M, Ongini E, Conti A, Zocchi C, Seminati M, Pocar D (1995) 2-[N--(3- Arylallylidene)hydrazino]adenosines showing A2A adenosine agonist properties and vasodilation activity. J Med Chem 38:3581-3585
198. Vollmann K, Qurishi R, Hockemeyer J,Müller CE (2008) Synthesis and properties of a new watersoluble prodrug of the adenosine A2A receptor antagonist MSX-2. Molecules 13:348-359
199. Volpini R, Camaioni E, Vittori S, Barboni L, Lambertucci C, Cristalli G (1998) Synthesis of new nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl- D-ribofuranuronamide. Helv Chim Acta 81:145-152
200. Volpini R, Camaioni E, Costanzi S, Vittori S, Klotz KN, Cristalli G (1999) Synthesis of di- and tri-substituted adenosine derivatives and their affinities at human adenosine receptor subtypes. Nucleosides Nucleotides 18:2511-2520
201. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2002) N6-Alkyl- 2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands. J Med Chem 45:3271-3279
202. Volpini R, Costanzi S, Lambertucci C, Portino FR, Taffi S, Vittori S, Klotz KN, Cristalli G (2004) Adenosine receptor agonists: synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives. ARKIVOC 301-311
203. Volpini R, Costanzi S, Lambertucci C, Vittori S, Martini C, Trincavelli ML, Klotz KN, Cristalli G (2005) 2- and 8-Alkynyl-9-ethyladenines: synthesis and biological activity at human and rat adenosine receptors. Purinergic Signal 1:173-181
204. Vu CB (2005) Recent advances in the design and optimization of adenosine A2A receptor antagonists. Curr Opin Drug Discov Dev 8:458-468
205. Vu CB, Pan D, Peng B, Sha L, Kumaravel G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Petter RC (2004a) Studies on adenosine A2A receptor antagonists: comparison of three core heterocycles. Bioorg Med Chem Lett 14:4831-4834
206. Vu CB, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Grant D, Hetu G, Chen L, Zhang J, Petter RC (2004b) Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2A receptor antagonists. J Med Chem 47:4291-4299 (Pubitemid 39045435)
207. Vu CB, Shields P, Peng B, Kumaravel G, Jin X, Phadke D, Wang J, Engber T, Ayyub E, Petter RC (2004c) Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2A receptor antagonists. Bioorg Med Chem Lett 14:4835-4838 (Pubitemid 39165577)
208. Vu CB, Pan D, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Grant D, Hetu G, Petter RC (2005) Novel diamino derivatives of [1,2,4]triazolo[1,5- a][1,3,5]triazine as potent and selective adenosine A2A receptor antagonists. J Med Chem 48:2009-2018
209. Wan W, Sutherland GR, Geiger JD (1990) Binding of the adenosine A2 receptor ligand [3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. J Neurochem 55:1763-1771
210. Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61:S101-S106
211. Williams M, Francis J, Ghai G, Braunwalder A, Psychoyos S, Stone GA, Cash WD (1987) Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. J Pharmacol Exp Ther 241:415-420 (Pubitemid 17111540)
212. Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310
213. Yan L, Burbiel JC, Maass A, Müller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537-576
214. Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC (2007) Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 375:133-144
215. Yao G, Haque S, Sha L, Kumaravel G, Wang J, Engber TM, Whalley ET, Conlon PR, Chang H, Kiesman WF, Petter RC (2005) Synthesis of alkyne derivatives of a novel triazolopyrazine as A2A adenosine receptor antagonists. Bioorg Med Chem Lett 15:511-515 (Pubitemid 40143117)
216. Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Müller CE, Linden J, Cunha RA, Chen JF (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346
217. Yuzlenko O, Kiec-Kononowicz K (2006) Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr Med Chem 13:3609-3625
218. Zablocki J, Palle V, Blackburn B, Elzein E, Nudelman G, Gothe S, Gao Z, Li Z, Meyer S, Belardinelli L (2001) 2-Substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucl Acids 20:343-360
219. Zhang X, Rueter JK, Chen Y, Moorjani M, Lanier MC, Lin E, Gross RS, Tellew JE, Williams JP, Lechner SM, Markison S, Joswig T, Malany S, Santos M, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Diaz JL, Saunders J, Slee DH (2008) Synthesis of N-pyrimidinyl-2- phenoxyacetamides as adenosine A2A receptor antagonists. Bioorg Med Chem Lett 18: 1778-1783
220. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (1996a) The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2A adenosine receptor antagonist. J Pharmacol Exp Ther 276:398-404 (Pubitemid 126660473)
221. Zocchi C, Ongini E, Ferrara S, Baraldi PG, Dionisotti S (1996b) Binding of the radioligand [3H]- SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117:1381-1386